Peroxisome proliferator-activated receptor (PPAR) α or γ does not change ischemic tolerance in hearts from type 2 diabetic mice

2002 ◽  
Vol 34 (6) ◽  
pp. A3
Author(s):  
Ellen Aasum ◽  
Andrew Carley ◽  
Terje S. Larsen ◽  
David Lseverson
Keyword(s):  
Ischemic Tolerance ◽  
Peroxisome Proliferator ◽  
Diabetic Mice ◽  
Peroxisome Proliferator Activated Receptor ◽  
Type 2 Diabetic

Cardioprotective effect of the PPAR ligand tetradecylthioacetic acid in type 2 diabetic mice

2011 ◽  
Vol 300 (6) ◽  
pp. H2116-H2122 ◽  
Author(s):  
Ahmed M. Khalid ◽  
Anne Dragøy Hafstad ◽  
Terje S. Larsen ◽  
David L. Severson ◽  
Neoma Boardman ◽  
...  
Keyword(s):  
Antioxidant Property ◽  
Cardiac Metabolism ◽  
Lipid Lowering ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Antidiabetic Therapy ◽  
Tetradecylthioacetic Acid ◽  
Ppar Ligand ◽  
Type 2 Diabetic

Tetradecylthioacetic acid (TTA) is a novel peroxisome proliferator-activated receptor (PPAR) ligand with marked hypolipidemic and insulin-sensitizing effects in obese models. TTA has recently been shown to attenuate dyslipidemia in patients with type 2 diabetes, corroborating the potential for TTA in antidiabetic therapy. In a recent study on normal mice, we showed that TTA increased myocardial fatty acid (FA) oxidation, which was associated with decreased cardiac efficiency and impaired postischemic functional recovery. The aim of the present study was, therefore, to elucidate the effects of TTA treatment (0.5%, 8 days) on cardiac metabolism and function in a hyperlipidemic type 2 diabetic model. We found that TTA treatment increased myocardial FA oxidation, not only in nondiabetic ( db/+) mice but also in diabetic ( db/db) mice, despite a clear lipid-lowering effect. Although TTA had deleterious effects in hearts from nondiabetic mice (decreased efficiency and impaired mitochondrial respiratory capacity), these effects were not observed in db/db hearts. In db/db hearts, TTA improved ischemic tolerance, an effect that is most likely related to the antioxidant property of TTA. The present study strongly advocates the need for investigation of the cardiac effects of PPAR ligands used in antidiabetic/hypolipidemic therapy, because of their pleiotropic properties.

Sign in / Sign up

Export Citation Format

Share Document